Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
MWN-AI** Summary
Anchor Line Partners, in association with Northwood Investors, has successfully finalized a major long-term lease with Stoke Therapeutics, securing a new 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, Massachusetts. This relocation, slated for late 2026 after the expiration of Stoke's current lease in Bedford, represents one of the largest commercial real estate agreements in the Greater Boston life sciences sector within the past year.
Stoke Therapeutics, a biotechnology firm focusing on RNA medicine, is advancing its investigational drug, zorevunersen, which is targeted at treating Dravet syndrome, a severe neurodevelopmental disorder characterized by recurrent seizures and cognitive impairments. The company, which was founded in 2015 and initially headquartered in Bedford, has made significant progress, moving from early clinical trials to late-stage development of zorevunersen in collaboration with Biogen.
Ian F. Smith, CEO of Stoke, emphasized the strategic significance of the new headquarters in fostering a collaborative culture essential for innovation. He noted that this move is pivotal as the company gears up to commercialize its first potential medicine while expanding its research initiatives.
Andrew Maher, Co-Founder of Anchor Line Partners, highlighted Waltham's robustness as a life sciences hub, maintaining its appeal even as the national biotech market experiences moderation. The new property features state-of-the-art facilities that are LEED Gold and WiredScore Platinum certified, offering significant operational efficiency and connectivity, crucial for Stoke's growth.
The transaction was facilitated by Cushman & Wakefield, showcasing Anchor Line Partners' acumen in supporting growth in the life sciences sector while meeting the evolving needs of innovative companies.
MWN-AI** Analysis
Anchor Line Partners’ recent acquisition of a 98,500 square-foot lease for Stoke Therapeutics in Waltham, Massachusetts, underscores notable trends within the biotech real estate market, particularly in the resilient Greater Boston area. This deal not only signifies a strategic relocation for Stoke as it prepares to commercialize its promising investigational medicine, zorevunersen, for Dravet syndrome, but it also reaffirms Waltham’s status as a burgeoning life sciences hub.
From a financial perspective, investors should closely monitor the developments surrounding Stoke Therapeutics (Nasdaq: STOK). The company's expansion into a larger, modern facility enhances its operational capacity and positions it for future innovation. Stoke's focus on RNA medicine and the advancing clinical trials for zorevunersen add significant value. As this product moves closer to potential commercialization, there is a tangible upside presented for shareholders, particularly as the incidence of Dravet syndrome creates a growing need for effective treatments.
Moreover, despite a national trend of moderation within the life sciences market, Waltham's market dynamics remain robust, driven by the area's talent density and logistical advantages. This lease showcases the attractiveness of well-placed biotech spaces that enable efficiency and collaboration — both critical components for innovation.
Investors might consider a diversified approach by looking into companies operating in similar markets or engaging in partnerships with firms like Anchor Line Partners, which is recognized for its value-add strategy in commercial real estate. As the biotech sector continues to evolve, positions in strategically located real estate investment trusts (REITs) focused on life sciences may offer an appealing proposition for long-term growth within this resilient market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts
Lease is One of the Largest in Greater Boston Life Sciences Over the Past Year
WALTHAM, Mass., Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters when the Company's current lease in Bedford, Massachusetts ends in late 2026.
Stoke is dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen as a first-in-class potential disease-modifying treatment for Dravet syndrome. Dravet syndrome is a severe neurodevelopmental disease that is characterized by recurrent seizures as well as significant cognitive and behavioral impairments.
Stoke established its first headquarters in Bedford in 2015. Zorevunersen was discovered in Bedford, and since then, the Company has advanced zorevunersen through early clinical testing into late-stage development. The Company is actively preparing to commercialize its first potential new medicine in the United States and is expanding its research into additional medicines using its proprietary technology platform.
"Stoke is on an important growth trajectory as we prepare to commercialize a first-in-class potential new medicine to treat Dravet syndrome, while also broadening our research efforts to identify more new medicines for severe diseases," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "This new Waltham site will help foster our culture of teamwork and collaboration that is essential to innovation and our work to deliver life-changing medicines for patients."
"While the national life sciences market has moderated, Waltham and the greater Route 128 corridor continue to prove their resilience as they support the biotech industry," said Andrew Maher, Co-Founder and Manager Partner, Anchor Line Partners. "This lease reflects the continued strength of the Greater Boston life sciences market and our commitment to delivering best-in-class environments that meet the evolving needs of innovative companies and their employees."
Waltham has emerged as one of the most compelling suburban life sciences hubs in the country, offering scale, talent and connectivity outside the urban core. The city and property offer immediate access to Route 128/I-95, I-90 and Route 2, making it a prime location for companies seeking operational efficiency and access to top talent. The property is LEED Gold and WiredScore Platinum certified, reinforcing the campus's commitment to sustainability and connectivity. The building's modern infrastructure and flexible lab-ready design made it a strategic fit for Stoke's next phase of expansion.
The Cushman & Wakefield team of Mitch Perez, Connor Barnes and Michael Weiss represented Stoke in the transaction. Michael O'Leary and Duncan Gratton, also of Cushman & Wakefield, handle leasing efforts at 245 Fifth Avenue.
This new lease exemplifies Anchor Line Partners' expertise in the life sciences sector and its focus on tenant satisfaction, long-term value creation and market-driven development strategy. For more information, visit 2455th.com.
About Anchor Line Partners
Anchor Line Partners is a Boston-based investment firm with $1.2 billion of commercial real estate assets under management. We specialize in value-add opportunities and developments in Greater Boston, creating strong, long-term economic assets for communities and producing desirable returns for our investors. Learn more at anchorlinepartners.com.
About Northwood Investors
Northwood Investors is a privately-owned, employee-held investment advisor with approximately $8 billion of assets under management across the US and Europe. Northwood employs a fundamental, value-driven investment strategy with a longer-term outlook. The Northwood team has deep experience in sourcing, executing and managing real estate transactions worldwide, ranging from office buildings and shopping centers to hotels and residential investments.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.
About Cushman & Wakefield
Cushman & Wakefield is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2024, the firm reported revenue of $9.4 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com.
SOURCE Anchor Line Partners
FAQ**
How will the new 98,500 square-foot lease in Waltham, MA, for Stoke Therapeutics Inc. STOK, impact the company’s ability to advance the clinical development of its potential disease-modifying medicine, zorevunersen, for Dravet Syndrome?
What specific features of the Waltham property make it a strategic fit for Stoke Therapeutics Inc. STOK’s next phase of expansion, and how do these align with their operational efficiency goals?
Given the current trends in the life sciences market, what factors contributed to the decision for Stoke Therapeutics Inc. STOK to secure this lease in a competitive Greater Boston market?
How does this lease support Stoke Therapeutics Inc. STOK's commitment to innovation and collaboration within the life sciences community, especially regarding the development of new RNA medicines?
**MWN-AI FAQ is based on asking OpenAI questions about Stoke Therapeutics Inc. (NASDAQ: STOK).
NASDAQ: STOK
STOK Trading
12.4% G/L:
$37.76 Last:
279,957 Volume:
$35.60 Open:
